The primary objective of the study is to assess the efficacy of FACTOR X in the prevention of
bleeding when given as routine prophylaxis over 12 months.
The secondary objectives of the study are:
1. To assess the pharmacokinetics of FACTOR X after a single dose of 50 IU/kg.
2. To assess the safety of FACTOR X when given as routine prophylaxis over 6 months (26